vs

Side-by-side financial comparison of LEXICON PHARMACEUTICALS, INC. (LXRX) and Valaris Ltd (VAL). Click either name above to swap in a different company.

LEXICON PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($5.5M vs $5.2M, roughly 1.1× Valaris Ltd). Valaris Ltd runs the higher net margin — 13798.1% vs -282.7%, a 14080.8% gap on every dollar of revenue. On growth, Valaris Ltd posted the faster year-over-year revenue change (405.9% vs 254.4%). Over the past eight quarters, LEXICON PHARMACEUTICALS, INC.'s revenue compounded faster (124.2% CAGR vs 29.5%).

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 1...

Valaris Limited is an offshore drilling contractor headquartered in Houston, Texas, and incorporated in Bermuda. It is the largest offshore drilling and well drilling company in the world. As of February 2025, it owned 52 rigs, including 36 offshore jackup rigs, 11 drillships, and 5 semi-submersible platform drilling rigs.

LXRX vs VAL — Head-to-Head

Bigger by revenue
LXRX
LXRX
1.1× larger
LXRX
$5.5M
$5.2M
VAL
Growing faster (revenue YoY)
VAL
VAL
+151.5% gap
VAL
405.9%
254.4%
LXRX
Higher net margin
VAL
VAL
14080.8% more per $
VAL
13798.1%
-282.7%
LXRX
Faster 2-yr revenue CAGR
LXRX
LXRX
Annualised
LXRX
124.2%
29.5%
VAL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LXRX
LXRX
VAL
VAL
Revenue
$5.5M
$5.2M
Net Profit
$-15.5M
$717.5M
Gross Margin
96.3%
-7850.0%
Operating Margin
-269.1%
Net Margin
-282.7%
13798.1%
Revenue YoY
254.4%
405.9%
Net Profit YoY
54.0%
436.6%
EPS (diluted)
$-0.04
$10.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LXRX
LXRX
VAL
VAL
Q4 25
$5.5M
$5.2M
Q3 25
$14.2M
$5.6M
Q2 25
$28.9M
$700.0K
Q1 25
$1.3M
Q4 24
$1.6M
$-1.7M
Q3 24
$1.7M
$3.9M
Q2 24
$1.6M
$4.8M
Q1 24
$1.1M
$2.6M
Net Profit
LXRX
LXRX
VAL
VAL
Q4 25
$-15.5M
$717.5M
Q3 25
$-12.8M
$188.1M
Q2 25
$3.3M
$115.1M
Q1 25
$-25.3M
Q4 24
$133.7M
Q3 24
$-64.8M
$64.6M
Q2 24
$-53.4M
$149.6M
Q1 24
$-48.4M
$25.5M
Gross Margin
LXRX
LXRX
VAL
VAL
Q4 25
96.3%
-7850.0%
Q3 25
99.9%
-7142.9%
Q2 25
99.9%
-56428.6%
Q1 25
97.6%
Q4 24
77.5%
24529.4%
Q3 24
95.9%
-11748.7%
Q2 24
89.7%
-9039.6%
Q1 24
97.2%
-17007.7%
Operating Margin
LXRX
LXRX
VAL
VAL
Q4 25
-269.1%
Q3 25
-85.9%
Q2 25
12.9%
Q1 25
-2034.8%
Q4 24
Q3 24
-3658.4%
Q2 24
-3423.3%
Q1 24
-4147.6%
Net Margin
LXRX
LXRX
VAL
VAL
Q4 25
-282.7%
13798.1%
Q3 25
-90.0%
3358.9%
Q2 25
11.3%
16442.9%
Q1 25
-2004.4%
Q4 24
-7864.7%
Q3 24
-3722.6%
1656.4%
Q2 24
-3304.2%
3116.7%
Q1 24
-4427.9%
980.8%
EPS (diluted)
LXRX
LXRX
VAL
VAL
Q4 25
$-0.04
$10.13
Q3 25
$-0.04
$2.65
Q2 25
$0.01
$1.61
Q1 25
$-0.07
Q4 24
$1.86
Q3 24
$-0.18
$0.88
Q2 24
$-0.17
$2.03
Q1 24
$-0.20
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LXRX
LXRX
VAL
VAL
Cash + ST InvestmentsLiquidity on hand
$96.2M
$599.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$107.5M
$3.2B
Total Assets
$185.0M
$5.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LXRX
LXRX
VAL
VAL
Q4 25
$96.2M
$599.4M
Q3 25
$116.0M
$662.7M
Q2 25
$139.0M
$503.4M
Q1 25
$194.8M
Q4 24
$238.0M
$368.2M
Q3 24
$258.4M
$379.3M
Q2 24
$310.0M
$398.3M
Q1 24
$355.6M
$494.1M
Stockholders' Equity
LXRX
LXRX
VAL
VAL
Q4 25
$107.5M
$3.2B
Q3 25
$120.2M
$2.4B
Q2 25
$129.4M
$2.3B
Q1 25
$123.0M
Q4 24
$145.9M
$2.2B
Q3 24
$178.5M
$2.1B
Q2 24
$240.0M
$2.2B
Q1 24
$288.9M
$2.0B
Total Assets
LXRX
LXRX
VAL
VAL
Q4 25
$185.0M
$5.3B
Q3 25
$205.9M
$4.6B
Q2 25
$225.6M
$4.5B
Q1 25
$297.7M
Q4 24
$298.4M
$4.4B
Q3 24
$321.1M
$4.3B
Q2 24
$373.4M
$4.4B
Q1 24
$417.2M
$4.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LXRX
LXRX
VAL
VAL
Operating Cash FlowLast quarter
$-17.2M
$72.2M
Free Cash FlowOCF − Capex
$-34.1M
FCF MarginFCF / Revenue
-655.8%
Capex IntensityCapex / Revenue
2044.2%
Cash ConversionOCF / Net Profit
0.10×
TTM Free Cash FlowTrailing 4 quarters
$159.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LXRX
LXRX
VAL
VAL
Q4 25
$-17.2M
$72.2M
Q3 25
$-23.8M
$198.1M
Q2 25
$17.0M
$120.0M
Q1 25
$-43.8M
Q4 24
$-178.8M
$124.6M
Q3 24
$-53.6M
$193.0M
Q2 24
$-48.5M
$11.5M
Q1 24
$-55.1M
$26.3M
Free Cash Flow
LXRX
LXRX
VAL
VAL
Q4 25
$-34.1M
Q3 25
$128.3M
Q2 25
$52.8M
Q1 25
Q4 24
$-179.8M
$12.9M
Q3 24
$-53.9M
$111.1M
Q2 24
$-48.8M
$-98.7M
Q1 24
$-125.0M
FCF Margin
LXRX
LXRX
VAL
VAL
Q4 25
-655.8%
Q3 25
2291.1%
Q2 25
7542.9%
Q1 25
Q4 24
-11600.7%
-758.8%
Q3 24
-3097.4%
2848.7%
Q2 24
-3017.3%
-2056.3%
Q1 24
-4807.7%
Capex Intensity
LXRX
LXRX
VAL
VAL
Q4 25
2044.2%
Q3 25
0.0%
1246.4%
Q2 25
9600.0%
Q1 25
Q4 24
66.5%
-6570.6%
Q3 24
17.6%
2100.0%
Q2 24
15.5%
2295.8%
Q1 24
0.0%
5819.2%
Cash Conversion
LXRX
LXRX
VAL
VAL
Q4 25
0.10×
Q3 25
1.05×
Q2 25
5.23×
1.04×
Q1 25
Q4 24
0.93×
Q3 24
2.99×
Q2 24
0.08×
Q1 24
1.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons